Neuroleptic dysphoria, comorbid drug abuse in schizophrenia and the emerging science of subjective tolerability - Towards a new synthesis

Journal of Dual Diagnosis

Volumn 1, Issue 2, 2005, Pages 83-93

  Awad, A George ^a,b   Voruganti, Lakshmi N P ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HUMBER RIVER REGIONAL HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Antipsychotic medications; Comorbid drug abuse; Dopamine dysregulation; Motivational and reinforcement behaviour; Neuroleptic dysphoria; Nucleus accumbens; Schizophrenia

Indexed keywords

ALCOHOL; AMPHETAMINE; CANNABIS; CHLORPROMAZINE; COCAINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; ILLICIT DRUG; METIROSINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADDICTION; ANXIETY; BRAIN DYSFUNCTION; DISEASE ASSOCIATION; DISTRESS SYNDROME; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG RECEPTOR BINDING; DYSPHORIA; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; MOTIVATION; NIGRONEOSTRIATAL SYSTEM; NUCLEUS ACCUMBENS; POSITRON EMISSION TOMOGRAPHY; REINFORCEMENT; REVIEW; SCHIZOPHRENIA; SELF MEDICATION; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBJECTIVE TOLERABILITY DISORDER; TREATMENT REFUSAL;

EID: 24144434958     PISSN: 15504263     EISSN: None     Source Type: Journal    
DOI: 10.1300/J374v01n02_06     Document Type: Review

References (48)

1. Awad A.G., Voruganti L.N.P. "New Antipsychotics, Compliance, Quality of Life and Subjective Tolerability - Are Patients Better Off?" Can. J. Psychiatry 2004;49: 297-302.
2. Awad A.G. "Subjective Response to Neuroleptics in Schizophrenia." Schizophr. Bull. 1993;19:609-618.
3. Van Putten T., Marder S.R. "Behavioural Toxicity of Antipsychotic Drugs." J. Clin. Psychiatry 1987;48:13-19.
4. Ayd F.J. "Drug Induced Depression - Facts or Fallacy!" N.Y. J. Med. 1958; 58:354.
5. Rifkin A., Quitkin F., Klein D.F. "Akinesia." Arch. G. Psychiatry 1975; 32:672-674.
6. Van Putten T. May PRA. "Akinetic Depression" in Schizophrenia-Arch. Gen. Psychiatry 1978;35:1101-1107.
7. Wise R.A. "Neuroleptic Induced Anhedonia: Recent Studies." In: Advances in Neuropsychiatry and Psychopharmacology. 1-Schizophrenia Research, Ed: Taminga, Schulz S.C. Raven Press, New York 1991;323-331.
8. Awad A.G., Hogan T.P., Voruganti L.N.P., Heslegrave R.J. "Subjective Experiences on Antipsychotic Medications: Implications for Outcome and Quality of Life." Int. Clin. Psychopharmacol. 1995;10(Suppl. 3): 123-132.
9. Singh M.M., Smith J.M. "Dysphoric Response to Neuroleptic Treatment in Schizophrenia and its Prognostic Significance." Dis. Ner. Syst. 1976;37:191-196.
10. Hogan T.P., Awad A.G., Eastwood M.R. "A Self-Report Scale Predictive of Drug Compliance in Schizophrenia: Reliability and Discriminative Ability." Psychol. Med. 1983;13:177-183.
11. Awad A.G., Hogan T.P. "Early Treatment Events and Prediction of Response to Neuroleptics in Schizophrenia." Prog. Neuropsychopharmacol. Biol. Psychiatry. 1985;9:585-588.
12. McNair D.M., Lorr M., Droppleman L. "Manual for the Profile of Mood States." Educational and Testing Services, San Diego, Calif. U.S.A., 1992.
13. Weiden P.J., Rapkin B., Mott T., Zymunt A., Goldman D., Horvitz-Lennon M., Frances A. "Rating of Medication Influences (ROMI) Scale in Schizophrenia." Schizophr. Bull. 1994;20:297-310.
14. Naber D., Walther A., Kirchere T., Hayek D., Holzback R. "Subjective Effects of Neuroleptic Predictive Compliance." In: Prediction of Neuroleptic Treatment Outcome in Schizophrenia: Concepts and Methods. Ed: Gaebel W., Awad A.G., Heidelberg, Springer-Verlag, 1994; 111-122.
15. Naber D.A. "Self-Rating Scale to Measure Subjective Effects of Neuroleptic Drugs, Relationship to Objective Psychopathology, Quality of Life and Other Clinical Variables." Int. Clin. Psychopharmacol. 1995;10(Supple 3): 133-138.
16. Voruganti L.N.P., Awad A.G. "Personal Evaluation of Transitions in Treatment (PETiT): A Scale to Measure Subjective Tolerability of Antipsychotic Medications." Schizophr. Res. 2002;56:37-46.
17. Awad A.G. "Antipsychotic Medications: Compliance and Attitudes Toward Treatment." Curr. Opin. Psychiatry, 2004.
18. Van Putten T. "Subjective Response as a predictor of outcome in pharmacotherapy." Arch. Gen. Psychiatry 1978;35:477-480.
19. Bartko G., Herczog I., Bekesly M. "Predicting Outcome of Neuroleptic Therapy on the Basis of Subjective Response and Early Clinical Improvement." J. Clin. Psychiatry 1987;48:363-365.
20. Voruganti L.N.P., Heslegrave R.J., Awad A.G. "Neuroleptic Dysphoria May Be the Missing Link Between Schizophrenia and Substance Abuse." J. Ner. Ment. Dis. 1997;185:463-465.
21. Brownie S., Garvin M., Roe M., Larkin C., O'Callaghan E. "Quality of Life in Schizophrenia: Insight and Subjective Response in Schizophrenia." J. Nerv. Ment. Dis. 1998;186:74-78.
22. Voruganti L., Cortese L., Oyewumi L., Cernovsky Z., Zirul S., Awad A. "Comparative Evaluation of Conventional and Novel Antipsychotic Drugs with Reference to Their Subjective Tolerability, Side Effect Profile and Impact on Quality of Life." Schizophr. Res. 2000;43:135-145.
23. Voruganti L., Cortese L., Oyewumi L., Kotteda V., Cernovsky Z., Zirul S., Awad A. "Switching from Conventional to Novel Antipsychotic Drugs: Results of a Prospective Naturalistic Study." Schizophr. Res. 2002;57:201-208.
24. Mueser K.T., Yarnold P.R., Levinson D.F. "Prevalence of Substance Abuse in Schizophrenia: Demographics and Clinical Correlates." Schizophr. Bull. 1990; 16:31-54.
25. Reigier D.A., Farmer M.E., Rae D.S. "Comorbidity of Mental Disorders with Alcohol and Other Drugs of Abuse." JAMA 1990;264:2511-2518.
26. Strakowski S.M., Tohen M., Flaum M., Amador X. "Substance Abuse in Psychotic Disorders: Associations with Affective Syndromes." Schizophr. Res. 1994; 14:73-81.
27. Buckley P.P. "Substance Abuse in Schizophrenia: A Review." J. Clin. Psychiatry 1998;95:26-30.
28. Khantzian E. "The Self-Medication Hypothesis of Addictive Disorders." Am. J. Psychiatry 1985;142:1259-1264.
29. Dalak G.W., Healy D.J., Meador-Woodruff M. "Nicotine Dependence in Schizophrenia: Clinical Phenomena and Laboratory Findings." Am. J. Psychiatry 1998;155:1490-1501.
30. Krystal J.H., D'Souza D.C., Madonick S., Petrakis I.L. "Towards a Rational Pharmacotherapy of Comorbid Substance Abuse in Schizophrenia Patients." Schizophr. Res. 1999;35(Suppl.):S35-S49.
31. Dixon L., Haas G., Weiden P., Sweeny J., Frances A.J. "Drug Abuse in Schizophrenic Patients with Clinical Correlates and Reasons for Use." Am. J. Psychiatry 1991;148:224-230.
32. Hambrecht M., Hafner H. "Substance Abuse and the Onset of Schizophrenia." Biol. Psychiatry. 1996;148:224-230.
33. Levy S., Robinson D.G., Solloways S. "Correlates of Substance Misuse in Patients with First Episode Schizophrenia and Schizoaffective Disorder." Acta Psychiat. Scand. 2001;1014:367-374.
34. Voruganti L., Slomka P., Zabel P., Costa G., So A., Mattar A., Awad A. "Subjective Effects of AMPT Induced Dopamine Depletion in Schizophrenia, The Correlation between D2 Binding Ratio and Dysphoric Responses." Neuropsychopharmacology 2001;25:642-650.
35. de Haan L., Lavalaye J., Linszen D., Dingemans P.M.A.J., Booij J. "Subjective Experiences and Striatal Dopamine D2 Receptor Occupancy in Patients with Schizophrenia Stabilized by Olanzapine or Risperidone." Am. J. Psychiatry 2000;157: 1019-1020.
36. Voruganti L., Awad A. "Is Neuroleptic Dysphoria a Variant of Drug Induced Extra Pyramidal Side-Effects?" Can. J. Psychiatry 2004;49:285-289.
37. Roberts D.C.S., Corcoran M.E., Fibiger H.C. "On the Role of Ascending Catechalamenergic Systems in Intravenous Self-Administration of Cocaine." Pharmacol. Biochem. Behav. 1977;6:615-620.
38. Wise R.A. "Addictive Drugs and Brain Stimulation Reward." Ann. Rev. Neurosci. 1996;19:319-330.
39. Russell K., Hagenmeyer-Houser S.H., Sanberg P.R. "Haloperidol- Induced Emotional Defecation: Possible Model for Neuroleptic Anxiety Syndrome." Psychopharmacology 1987;91:45-49.
40. Sandberg P.R., Russell K.H., Hagenmyer-Houser S.H., Giordano M., Zybrycki E.M., Garver D.L. "Neuroleptic-Induced Emotional Defecation: Effects of Scopolamine and Haloperidol." Psychopharmacology 1989;99:60-63.
41. Fibiger H.C. Neurobiology of Depression-Focus on Dopamine. Adv. Biochem Psychopharmacol. 1995;49:1-7.
42. Volkow N.D., Fowler J.S., Wang G.J. "Imaging Studies on the Role of Dopamine in Cocaine, Reinforcement and Addiction in Humans." J. Psychopharmacol. 1999;13:337-345.
43. Volkow N.D. "Drug Abuse and Mental Illness: Progress in Understanding Comorbidity." Am. J. Psychiatry 2001;158:1181-1183.
44. Chambers R., Krystal J.H., Self D.W. "A Neurobiological Basis for Substance Abuse Comorbidity in Schizophrenia." Biol. Psychiatry 2001;50:71-83.
45. Haertzen C.A. "Addiction Research Centre Inventory (ARCI): Development of General Drug Estimation Scale." J. Ner. Ment. Dis. 1965;141:300-307.
46. Verhoeff N.P., Christensen B.K., Hussey D., Lee M., Papatheodorald G., Kapur S. "Effects of Catecholamine Depletion on D2 Receptors Binding Motivation and Attentiveness in Humans. A Replication Study." Pharmacol. Biochem. Behav. 2003;74:425-432.
47. Davis K.L., Kahn R.S., Ko G., Davidson M. "Dopamine and Schizophrenia: A Review on Reconceptualization." Am. J. Psychiatry 1991;148:1474-1486.
48. O'Donnell P., Greene J., Pabello N., Lewis B.L., Grace A.A. "Modulation of Cell Firing in the Nucleus Accumbens." Ann N.Y. Acad. Sci. 1999;877:157-175.